(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol
CAS: 127852-28-2
Ref. TR-B416125
5g | 118,00 € | ||
25g | 445,00 € | ||
100g | 1.239,00 € |
Informação sobre produto
- (alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)-Benzenemethanol
- (1R)-1-[3,5-Bis(Trifluoromethyl)phenyl]ethanol
- (1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethan-1-ol
- (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol
- (R)-1-(3,5-Bis(Trifluoromethyl)Phenyl)Ethan-1-Ol
- (R)-1-(3,5-Bis-trifluoromethylphenyl)ethanol
- (R)-1-3,5-Bis(trifluoromethyl) phenylethanol
- (R)-1-[3,5-Bis(Trifluoro-Methyl)-Phenyl]Ethanol
- (R)-1-[Bis-3,5-(Trifluoromethyl)Phenyl]Ethanol
- (R)-[3,5-Bis(trifluoromethyl)phenyl]ethanol
- Ver mais sinónimos
- (R)-bis-3,5-trifluoromethyl-1-phenylethanol
- (αR)-α-Methyl-3,5-bis(trifluoromethyl)benzenemethanol
- 1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethanol
- 1R)-1-[3,6-Bis(Trifluoromethyl)Phenyl]Ethanol
- Aprepitant Intermediate
- Benzenemethanol, A-Methyl-3,5-Bis(Trifluoromethyl)-, (Ar)-
- Benzenemethanol,a-methyl-3,5-bis(trifluoromethyl)-,(R)-
- R-Mbt-Pel
Applications (R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol is an intermediate in the synthesis of Aprepitant (A729800), a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic.
References Vankawala, P.J., et. al.: Synthetic Comm., 37, 3439 (2007); Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998); Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001); Van Belle, S., et al.: Cancer, 94, 3032 (2002); Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006)
Propriedades químicas
Consulta técnica sobre: TR-B416125 (R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.